Chromagen-3M agreement targets diagnostics
This article was originally published in Clinica
Chromagen, a US development-stage IVD company based in San Diego, has formalised its technology development agreement with 3M which has already resulted in solid phase extraction chemistries. Under the agreement, Chromagen has worldwide, exclusive rights to the application of the technology in infectious disease diagnostics. The two companies have set up a joint committee to direct development of the technology and promote business opportunities.